Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …

In the era of targeted therapy, predictive biomarker testing has become increasingly
important for non-small cell lung cancer. Of multiple predictive biomarker testing methods …

Therapy with anti-PD-L1 immune check-point inhibitors is approved for several cancers,
including advanced urothelial carcinomas. PD-L1 prevalence estimates vary widely in …

Abstract Programmed death ligand-1 (PD-L1) immunohistochemistry is used to guide
treatment decisions regarding the use of checkpoint immunotherapy in the management of …

Introduction Programmed death-ligand 1 (PD-L1) is used as a biomarker for anti–
programmed cell death protein-1 (PD-1) or anti-PD-L1 immunotherapies in NSCLC. We …

While the importance of programmed death-ligand 1 (PD-L1), mutation burden caused by
microsatellite instability (MSI), and CD8+ tumor infiltrating lymphocytes (TILs) has become …

Programmed cell death ligand 1 (PD‐L1) immunohistochemistry is used to determine which
patients with advanced non‐small‐cell lung cancer (NSCLC) respond best to treatment with …

Simple Summary Immune checkpoint inhibitors are expected to be used in clinical practice
to treat thyroid cancer. Programmed cell death ligand 1 (PD-L1) is the ligand expressed on …

Context.—Rapid advancements in the understanding and manipulation of tumor-immune
interactions have led to the approval of immune therapies for patients with non–small cell …

Programmed cell death ligand‐1 (PD‐L1) detection assays have not been standardized for
patients with colorectal cancer, and the prognostic value of PD‐L1 expression is unclear. We …